The NGS panel yielded 10 additional patients with a LP/P variant, 3 LP/P variants in the PAH patients previously tested negative for LP/P variants in BMPR2 and SMAD9 and 7 LP/P variants in the PAH group diagnosed after 2018. Here, BMPR2 is linked to pulmonary arterial hypertension.